Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03865381 · ClinicalTrials.gov registry record · NA

Onduo Virtual Diabetes Clinic Study

A NA study of Diabetes Mellitus, Type 2, sponsored by Verily Life Sciences.

Completed
Registry status
NA
Development phase
60
Enrollment target
2
Study locations

NCT03865381 is a NA study of Diabetes Mellitus, Type 2 that has completed, run by Verily Life Sciences. The registered enrollment target is 60 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03865381, a NA study of Diabetes Mellitus, Type 2, has completed, sponsored by Verily Life Sciences.

COMPLETED
Registry status
NA
Development phase
60 participants
Enrollment target
2
Study locations

Study Summary

This is a prospective, single arm study designed to evaluate the change in hemoglobin A1c after 4 months of participation in the Onduo Virtual Diabetes Clinic (VDC) in individuals with Type 2 diabetes and suboptimal glycemic control.

Conditions Studied

Interventions

  • DEVICE Onduo App

Study Locations (2)

California

  • Palo Alto Medical Foundation - Palo Alto

Pennsylvania

  • Premier Medical Associates - Monroeville

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2019-02-08
Est. Completion 2020-10-15
Phase NA

Sponsor

Verily Life Sciences

10 total trials

What the Registry Record Tells You About NCT03865381

The ClinicalTrials.gov registry entry for NCT03865381 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower). The listed sponsor is Verily Life Sciences, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 1 intervention - of which Onduo App is the first listed.

NCT03865381 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT03865381 about?

NCT03865381 is a clinical study titled "Onduo Virtual Diabetes Clinic Study". This is a prospective, single arm study designed to evaluate the change in hemoglobin A1c after 4 months of participation in the Onduo Virtual Diabetes Clinic (VDC) in individuals with Type 2 diabetes and suboptimal glycemic control.

What is the current status of trial NCT03865381?

This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2019-02-08. Estimated completion is 2020-10-15.

What conditions does trial NCT03865381 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.

What interventions are being tested in trial NCT03865381?

The interventions under investigation include: Onduo App (DEVICE).

Who is sponsoring clinical trial NCT03865381?

This trial is sponsored by Verily Life Sciences, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03865381 being conducted?

This trial has 2 study locations across California, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes Mellitus, Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.